![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Horizontal Tabs
PDB ID |
Structure Details |
Compound ID |
PARP14 macrodomain 2 with ligand MnK2-13 |
|
|
PARP14 macrodomain 3 with fragment N13417a |
FM010005a |
|
PARP14 macrodomain 3 with fragment N08149b |
FM001707a |
|
PARP14 macrodomain 3 with fragment N13681a |
FM001999a |
|
PARP14 macrodomain 3 with fragment N13729a |
XS106503b |
|
PARP14 macrodomain 3 with fragment N13734a |
FM001875a |
|
PARP14 macrodomain 3 with fragment N13856a |
FM001884a |
|
PARP14 macrodomain 3 with fragment N13979a |
FM010067a |
|
PARP14 macrodomain 3 with fragment N13857a |
FM002036a |
|
PARP14 macrodomain 3 with fragment N13848a |
FM002044a |
|
PARP14 macrodomain 3 with fragment N13987a |
FM001702a |
|
PARP14 macrodomain 3 with fragment N14095a |
FM001958a |
|
PARP14 macrodomain 3 with fragment N13660a |
FM001909a |
|
PARP14 macrodomain 3 with fragment N13844a |
FM002207a |
|
PARP14 macrodomain 3 with fragment N13767a |
FM001942a |
|
PARP14 macrodomain 3 with fragment N13462a |
FM002062a |
|
PARP14 macrodomain 3 with fragment N14015a |
XS097881b |
|
PARP14 macrodomain 3 with fragment N13888a |
FM002205a |
|
PARP14 macrodomain 3 with fragment N13605a |
FM010020a |
Protein expression and purification
Macrodomain proteins (PARP14 MD1, MD2, MD2SERmut and MD3) were expressed using constructs that add tobacco etch virus (TEV) protease-cleavable His6-tags. Transformed BL21(DE3)-R3-pRARE cells were grown at 37 °C in LB medium (Miller) supplemented with appropriate antibiotics until OD600 reached 0.5‒0.6, then cooled to 18 °C and supplemented with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at an OD600 of 0.8 to induce protein expression overnight. For purification of in vivo biotinylated macrodomain proteins, the constructs were transformed into BL21(DE3)-R3-BirA cell line (BL21 derivative coexpressing BirA using a pACYC coexpression vector). Cells were grown at 37 °C in LB medium (Miller) until OD600 reached 0.5–0.6, then cooled to 18 °C and supplemented with 0.5 mM D-biotin dissolved in 10 mM bicine (pH 8.3) and 0.5 mM IPTG at an OD600 of 0.8 to induce protein expression overnight. Cell pellets re-suspended in lysis buffer (50 mM HEPES (pH 7.4), 500 mM NaCl, 20 mM imidazole, 5 % glycerol, 0.5 mM tris(2-carboxyethyl)phosphine [TCEP], 1:2,000 Calbiochem protease inhibitor cocktail set III) were quickly thawed on ice and lysed by high pressure homogenisation. Following cell lysis, DNA was precipitated with 0.15 % polyethyleneimine (PEI) and insoluble cell debris was removed by centrifugation (36000×g, 1 h, 4 °C). His6- (-biotin) tagged proteins were purified using Ni-Sepharose resin (GE Healthcare) and eluted stepwise in binding buffer with 40–250 mM imidazole. A high salt wash with 1 M NaCl was combined with the first elution step including 40 mM imidazole. As required, the His6-tag was removed from the macrodomain proteins at 4 °C overnight using recombinant TEV protease (used 1:40 -1:100 (w/w)) before gel filtration (Superdex 75 16/60, GE Healthcare) in GF buffer (25 mM HEPES (pH 7.4), 300 mM NaCl, 5 % glycerol, 0.5 mM TCEP). Proteins with removed His6- tag were additionally passed over Ni-Sepharose resin as a final purification step. In the case of PARP14 MD2 and MD3 purification for crystallisation, TEV His6-tag cleavage after the first Ni-IMAC purification step was combined with overnight dialysis using SnakeSkin® Dialysis Tubing, 3500 MWCO (Thermo Scientific). The dialysed sample was passed over Ni-Sepharose resin before purification by gel filtration (Superdex 75 16/60) and further purification steps. For PARP14 MD3 the GF buffer contained 20 mM HEPES (pH 7.4), 300 mM NaCl, 10 % glycerol and 0.5 mM TCEP. Apart from Ni-IMAC rebinding, all purification steps were carried out at 4 °C.
AlphaScreen assay
Assays were performed with minor modifications from the manufacturer’s protocol (PerkinElmer) [27,28]. All reagents were diluted in buffer containing 25 mM HEPES (pH 7.4), 100 mM NaCl, 0.5 mM TCEP, 0.1 % BSA and 0.05 % CHAPS and allowed to equilibrate to RT before addition to plates. The assays were run in 20 µL volumes in low-volume 384-well plates (ProxiPlate™-384 Plus, PerkinElmer) at RT. To determine ideal assay concentrations of the corresponding macrodomain protein and the macrodomain AlphaScreen peptide (a biotinylated and ADP-ribosylated 11 residue sequence), 4 µL volumes of peptide (0-16 μM; final assay concentration: 0‑3.2 μM) were incubated with 4 µL volumes of His6-tagged macrodomain protein (0-16 μM; final assay concentration: 0-3.2 μM) in 4 µL buffer for 30 min at RT in foil-sealed plates. For compound screening and IC50 characterisation, 12 µL of a solution containing peptide and His6‑tagged macrodomain protein in the pre-determined assay concentrations in assay buffer were incubated for 30 min at RT with 50 nL or 100 nL compound solution (pre-dispensed into the assay plate from 10 mM or 50 mM DMSO stocks using an Echo 550 (Labcyte)). Then, 8 µL of streptavidin-coated donor beads (7 μg/ml) and nickel chelate acceptor beads (7 μg/ml) (Perkin Elmer AlphaScreen™ Histidine (Nickel Chelate) Detection Kit) were added under low light conditions and plates were incubated for 60 min at RT protected from light. Plates were read on a PHERAstar FS plate reader (BMG Labtech) using an AlphaScreen 680 excitation/570 emission filter set. Alternatively for counterscreening of the compounds, 12 µL of 75 nM biotinylated and His6-tagged linker peptide (PerkinElmer) was added to 50 nL or 100 nL of the compounds and plates were processed as described above.
Biolayer Inteferometry
Kinetic ligand-binding measurements were performed using an Octet RED384 BLI instrument (fortéBio) [29]. Superstreptavidin (SSA) biosensors were loaded with biotinylated macrodomain protein and equilibrated for 120 sec in assay buffer (25 mM HEPES (pH 7.4), 100 mM NaCl, 0.01 % Tween 20). Association and dissociation were monitored for 240 sec each in assay buffer at 25 °C. For compound characterisation, compounds were typically prepared as seven 1:1 serial dilutions starting from 10 µM or 50 µM. Binding to the reference sensors (no protein attached) was subtracted before calculations and data was processed using the fortéBio analysis software provided by the manufacturer.
Crystallisation of PARP14 MD2 with MnK2-13
Surface entropy reduction (SER) mutations were introduced into PARP14 MD2 (A994−N1191) by the overlapping PCR method. Several mutants were prepared, of which construct PARP14A-c013 with K1048S, K1154S, K1158S, and K1162S mutation could be crystallized with MnK2-13. For protein crystallization, purified PARP14A-c013 was buffer exchanged into 20 mM HEPES (pH 7.4), 500 mM NaCl, 5% glycerol, and 0.5 mM TCEP, and concentrated to 16 mg/mL, using 10 kDa MWCO centrifugal concentrators (Millipore). MnK2-13 inhibitor dissolved to 50 mM in DMSO was added to a final concentration of 1.0 mM (2 % DMSO) and incubated on ice for approximately 30 min. The sample was centrifuged at 14,000 rpm for 10 min at 4 °C prior to setting up 150 nL volume sitting drops at three ratios (2:1, 1:1, or 1:2 protein−inhibitor complex to crystallization solution). A crystal was obtained with a 1:2 ratio of protein to a crystallization solution consisting of 0.8 M sodium phosphate monobasic, 0.8 M potassium phosphate dibasic, and 0.1 M HEPES at pH 7.5 and was cryoprotected in mother liquor supplemented with 25 % ethylene glycol before flash-freezing in liquid nitrogen for data collection. Diffraction data were collected at the Diamond Light Source (Harwell, UK) beamline I02.
Crystallisation of PARP14 MD3 with fragments
PARP14 MD3 apo was crystallised by mixing on pre-cooled sitting drop crystallisation plates 100 nL of 30 mg/mL protein in 20 mM HEPES (pH 7.4), 300 mM NaCl, 10 % glycerol, 0.5 mM TCEP with 50 nL of reservoir solution containing 80 mM KBr and 30 % PEG2000MME and adding 15 nL of a crystal seed solution obtained from a previous crystallisation experiment, diluted 1:500 from the stock in 90 mM KBr and 30 % PEG2000MME. The seeds were prepared from a single crystal growing in 90 mM KBr and 30 % PEG2000MME which was smashed to seeds using a 3 mm PTFE seed bead (Fisher Scientific) using standard laboratory vortex at full speed in 100 µL reservoir solution. Crystal growth was completed after 24 hours with incubation at 4 °C.
PARP14 MD3 apo crystals were soaked with compounds from the DSPL2.0 library consisting of 776 fragments at 500 mM in DMSO-d6 (and a subset in ethylene glycol). Soaking was performed by acoustically transferring 17.5 nL of compound solution to the crystallisation drop using an Echo 550 (Labcyte) [30] resulting in a final compound concentration of 50 mM with 10 % DMSO, calculated based on the initial drop volume. Crystals were incubated for 4-6 hours at 4 °C and then harvested (without cryoprotection) and cryocooled before X-ray diffraction data collection on the beamline I04-1 at Diamond Light Source (Harwell, UK).
Coordinates and structure factors for all data sets are deposited in the RCSB Protein Data Bank. Data collection and refinement statistics are available from the PDB pages.
Structure determination
PARP14 MD2
The diffraction data collected from a PARP14 MD2-MnK2-13 co-crystal was processed using MOSFLM [31] and AIMLESS [32]. The structure was solved by molecular replacement using PHASER [33] and a published structure of PARP14 MD2 (PDB ID 3Q71) as a search model. There was one molecule of PARP14 MD2 in the asymmetric unit. Coot [34] and REFMAC5 [35] were used for building the model and refinement. MOLPROBITY [36] was used for model validation and analysis.
PARP14 MD3
X-ray diffraction data collected for the PARP14 MD3 fragment screen was processed using the Diamond autoprocessing pipeline, utilising xia2 [37] and DIALS [38], and programs from the CCP4 suite [39]. Electron-density maps were generated using the XChemExplorer [40] via DIMPLE [41]. Ligand restraints were generated with AceDRG [42] and ligand binding was detected with PanDDA [43], with ligands built into PanDDA event maps. Iterative refinement and manual model correction was performed using REFMAC5 [35] and Coot [34], respectively.
- B.A. Gibson, W.L. Kraus. (2012) New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nature Reviews Molecular Cell Biology 13, 411–424.
- P. Bai. (2015) Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance. Molecular Cell 58 947–958.
- S. Goenka, M. Boothby. (2006) Selective potentiation of Stat-dependent gene expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor. PNAS. 103, 4210–4215.
- S. Goenka, H.C. Sung, M. Boothby. (2007) Collaborator of Stat6 (CoaSt6)-associated Poly(ADP-ribose) Polymerase Activity Modulates Stat6-dependent Gene Transcription. Journal of Biological Chemistry 282, 18732–18739.
- P. Mehrotra, J.P. Riley, R. Patel, F. Li, L. Voss, S. Goenka. (2011) PARP-14 Functions as a Transcriptional Switch for Stat6-dependent Gene Activation. Journal of Biological Chemistry 286, 1767–1776.
- S.H. Cho, S. Goenka, T. Henttinen, P. Gudapati, A. Reinikainen, C.M. Eischen, R. Lahesmaa, M. Boothby. (2009) PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood 113, 2416–2425.
- S.H. Cho, A.K. Ahn, P. Bhargava, C.-H. Lee, C.M. Eischen, O. McGuinness, M. Boothby. (2011) Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family. PNAS 108, 15972–15977.
- A. Barbarulo, V. Iansante, A. Chaidos, K. Naresh, A. Rahemtulla, G. Franzoso, A. Karadimitris, D.O. Haskard, S. Papa, C. Bubici. (2013) Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. Oncogene 32, 4231–4242.
- Human Protein Atlas available from www.proteinatlas.org.
- M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, Å. Sivertsson, C. Kampf, E. Sjöstedt, A. Asplund, I. Olsson, K. Edlund, E. Lundberg, S. Navani, C.A.-K. Szigyarto, J. Odeberg, D. Djureinovic, J.O. Takanen, S. Hober, T. Alm, P.-H. Edqvist, H. Berling, H. Tegel, J. Mulder, J. Rockberg, P. Nilsson, J.M. Schwenk, M. Hamsten, K. von Feilitzen, M. Forsberg, L. Persson, F. Johansson, M. Zwahlen, G. von Heijne, J. Nielsen, F. Pontén. (2015) Proteomics. Tissue-based map of the human proteome. Science 347, 1260419.
- W. Huang, M. Goldfischer, S. Babayeva, Y. Mao, K. Volyanskyy, N. Dimitrova, J.T. Fallon, M. Zhong. (2015) Identification of a novel PARP14-TFE3 gene fusion from 10-year-old FFPE tissue by RNA-seq. Genes, Chromosomes Cancer. 54, 500–505.
- P. Mehrotra, A. Hollenbeck, J.P. Riley, L. Fang, R.J. Patel, N. Akhtar, S. Goenka. (2013) PARP-14 and its enzyme activity regulates Th2 differentiation and allergic airway disease. Journal of Allergy and Clinical Immunology 131, 521–531.
- P. Mehrotra, P. Krishnamurthy, J. Sun, S. Goenka, M.H. Kaplan. (2015) Poly-ADP-ribosyl polymerase-14 promotes T helper 17 and follicular T helper development. Immunology 146, 537–546.
- A.K.L. Leung, S. Vyas, J.E. Rood, A. Bhutkar, P.A. Sharp, P. Chang. (2011) Poly(ADP-Ribose) Regulates Stress Responses and MicroRNA Activity in the Cytoplasm. Molecular Cell 42, 489–499.
- R. Zaffini, G. Gotte, M. Menegazzi. (2018) Asthma and poly(ADP-ribose) polymerase inhibition: A new therapeutic approach. Drug Design, Development and Therapy 12, 281–293.
- P. Krishnamurthy, M.H. Kaplan. (2016) STAT6 and PARP Family Members in the Development of T Cell-dependent Allergic Inflammation. Immune Network 16, 201–210.
- H. Iwata, C. Goettsch, A. Sharma, P. Ricchiuto, W.W. Bin Goh, A. Halu, I. Yamada, H. Yoshida, T. Hara, M. Wei, N. Inoue, D. Fukuda, A. Mojcher, P.C. Mattson, A.-L. Barabási, M. Boothby, E. Aikawa, S.A. Singh, M. Aikawa. (2016) PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. Nature Communications 7, 1–19.
- G. Caprara, E. Prosperini, V. Piccolo, G. Sigismondo, A. Melacarne, A. Cuomo, M. Boothby, M. Rescigno, T. Bonaldi, G. Natoli. (2018) PARP14 Controls the Nuclear Accumulation of a Subset of Type I IFN–Inducible Proteins. Journal of Immunology, ji1701117.
- B. Peng, A.G. Thorsell, T. Karlberg, H. Schüler, S.Q. Yao. (2017) Small Molecule Microarray Based Discovery of PARP14 Inhibitors. Angewandte Chemie - International Edition 56, 248–253.
- K. Upton, M. Meyers, A.-G. Thorsell, T. Karlberg, J. Holechek, R. Lease, G. Schey, E. Wolf, A. Lucente, H. Schüler, D. Ferraris. (2017) Design and synthesis of potent inhibitors of the mono(ADP-ribosyl)transferase, PARP14. Bioorganic & Medical Chemistry Letters 27, 5–9.
- M. Yoneyama-Hirozane, S. Matsumoto, Y. Toyoda, K.S. Saikatendu, Y. Zama, K. Yonemori, M. Oonishi, T. Ishii, T. Kawamoto. (2017) Identification of PARP14 inhibitors using novel methods for detecting auto-ribosylation. Biochemical and Biophysical Research Communications 486, 626–631.
- E. Wahlberg, T. Karlberg, E. Kouznetsova, N. Markova, A. Macchiarulo, A.-G. Thorsell, E. Pol, A. Frostell, T. Ekblad, D. Oncu, B. Kull, G.M. Robertson, R. Pellicciari, H. Schuler, J. Weigelt. (2012) Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nature Biotechnology 30, 283–288.
- M. Moustakim, K. Riedel, M. Schuller, A.P. Gehring, O.P. Monteiro, S.P. Martin, O. Fedorov, J. Heer, D.J. Dixon, J.M. Elkins, S. Knapp, F. Bracher, P.E. Brennan. (2018) Discovery of a novel allosteric inhibitor scaffold for polyadenosine-diphosphate-ribose polymerase 14 (PARP14) macrodomain 2. Bioorganic & Medicinal Chemistry.
- A.H. Forst, T. Karlberg, N. Herzog, A.G. Thorsell, A. Gross, K.L.H. Feijs, P. Verheugd, P. Kursula, B. Nijmeijer, E. Kremmer, H. Kleine, A.G. Ladurner, H. Schüler, B. Lüscher. (2013) Recognition of mono-ADP-ribosylated ARTD10 substrates by ARTD8 macrodomains. Structure 21, 462–475.
- C.M. Nicolae, E.R. Aho, K.N. Choe, D. Constantin, H.J. Hu, D. Lee, K. Myung, G.L. Moldovan. (2015) A novel role for the mono-ADP-ribosyltransferase PARP14/ARTD8 in promoting homologous recombination and protecting against replication stress. Nucleic Acids Research 43, 3143–3153.
- M. Schuller, K. Riedel, I. Gibbs-Seymour, K. Uth, C. Sieg, A.P. Gehring, I. Ahel, F. Bracher, B.M. Kessler, J.M. Elkins, S. Knapp. (2017) Discovery of a Selective Allosteric Inhibitor Targeting Macrodomain 2 of Polyadenosine-Diphosphate-Ribose Polymerase 14. ACS Chemical Biology 12, 2866–2874.
- PerkinElmer, A Practical Guide to working with AlphaScreen, User Guide. (2004). www.perkinelmer.com.
- M. Philpott, J. Yang, T. Tumber, O. Fedorov, S. Uttarkar, P. Filippakopoulos, S. Picaud, T. Keates, I. Felletar, A. Ciulli, S. Knapp, T.D. Heightman. (2011) Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Molecular BioSystems 7, 2899–2908.
- R. Tobias, S. Kumaraswamy, Biomolecular Binding Kinetics Assays on the Octet Platform, Appl. Note by fortéBio (Pall Life Sci. (2013)). http://www.biophysics.bioc.cam.ac.uk/wp-content/uploads/2011/02/ForteBio_App_Note_14.pdf.
- P.M. Collins, T. Ng, R. Talon, K. Nekrosiute, N.M. Pearce, F. Von Delft. (2017) Gentle, fast and effective crystal soaking by acoustic dispensing. Acta Crystallographica Section D: Structural Biology 73, 246–255.
- A.G.W. Leslie, H.R. Powell. (2007) Processing Diffraction Data with Mosflm. Evolving Methods for Macromolecular Crystallography 245, 41–51.
- P.R. Evans. (2011) An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallographica Section D 67, 282–292.
- A.J. McCoy, R.W. Grosse-Kunstleve, P.D. Adams, M.D. Winn, L.C. Storoni, R.J. Read. (2007) Phaser crystallographic software. Journal of Applied Crystalography 40, 658–674.
- P. Emsley, B. Lohkamp, W.G. Scott, K. Cowtan. (2010) Features and development of Coot. Acta Crystallographica Section D: Biological Crystallography 66, 486–501.
- G.N. Murshudov, P. Skubák, A.A. Lebedev, N.S. Pannu, R.A. Steiner, R.A. Nicholls, M.D. Winn, F. Long, A.A. Vagin. (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallographica Section D: Biological Crystallography 67, 355–367.
- V.B. Chen, W.B. Arendall, J.J. Headd, D.A. Keedy, R.M. Immormino, G.J. Kapral, L.W. Murray, J.S. Richardson, D.C. Richardson. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallographica Section D 66, 12–21.
- G. Winter (2010) xia2: An Expert System for Macromolecular Crystallography Data Reduction, Journal of Applied Crystallography 43, 186–190.
- D.G. Waterman, G. Winter, R.J. Gildea, J.M. Parkhurst, A.S. Brewster, N.K. Sauter, G. Evans. (2016) Diffraction-geometry refinement in the DIALS framework. Acta Crystallographica Section D: Structural Biology 72, 558–575.
- M.D. Winn, C. Charles, K.D. Cowtan, E.J. Dodson, P. Emsley, P.R. Evans, R.M. Keegan, E.B. Krissinel, A.G.W. Leslie, A. McCoy, S.J. McNicholas, G.N. Murshudov, N.S. Pannu, E.A. Potterton, H.R. Powell, R.J. Read, A. Vagin, K.S. Wilson. (2011) Overview of the CCP4 suite and current developments. Acta Crystallographica Section D: Biological Crystallography 67, 235–242.
- T. Krojer, R. Talon, N. Pearce, P. Collins, A. Douangamath, J. Brandao-Neto, A. Dias, B. Marsden, F. Von Delft. (2017) The XChemExplorer graphical workflow tool for routine or large-scale protein–ligand structure determination research papers. Acta Crystallographica Section D: Structural Biology 73, 267–278.
- M. Wojdyr, R. Keegan, G.W. Winter, A. Ashton. DIMPLE - a pipeline for the rapid generation of difference maps from protein crystals with putatively bound ligands. Acta Crystallographica Section A. 69, s299.
- F. Long, R.A. Nicholls, P. Emsley, S. Grazulis, A. Merkys, A. Vaitkus, G.N. Murshudov. (2017) AceDRG: a stereochemical description generator for ligands research papers, Acta Crystallographica Section D: Structural Biology 73, 112–122.
- N.M. Pearce, T. Krojer, A.R. Bradley, P. Collins, R.P. Nowak, R. Talon, B.D. Marsden, S. Kelm, J. Shi, C.M. Deane, F. Von Delft. (2017) A multi-crystal method for extracting obscured crystallographic states from conventionally uninterpretable electron density. Nature Communications 8, 1–8.
We respectfully request that this document is cited using the DOI value as given above if the content is used in your work.